Safety and efficacy of live attenuated varicella vaccine for preventing varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation: A Prospective Single-Center Study
Not Applicable
Recruiting
- Conditions
- Zoster
- Registration Number
- JPRN-UMIN000013799
- Lead Sponsor
- Division of Hematology, Saitama Medical Center, Jichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have a serious active infection 2) Patients who have a high fever above 37.5 degrees when they receive vaccination 3) Patients who have severe acute illness 4) Patients who experienced an anaphylactic shock due to vaccinations 5) Patients who are or may be pregnant 6) Patients with serious mental disorder 7) Patients who developed VZV disease after allogeneic HSCT 8) Patients with VZV-seronegative before allogeneic HSCT 9) Patients who received inactivated vaccine within 1 week or other live attenuated vaccine within 4 weeks 10) Patients who received transfusions or gamma globulin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidence of VZV disease
- Secondary Outcome Measures
Name Time Method 1)Adverse effect of vaccine 2)VZV antibody titer before and after vaccination 3)VZV specific CTL before and after vaccinations 4)Factors influencing VZV antibody titer and VZV specific CT